http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2010112837-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10T436-14 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4523 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 |
| filingDate | 2008-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2010112837-A |
| titleOfInvention | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND CHEMOTHERAPEUTIC AGENTS AND METHODS OF APPLICATION |
| abstract | 1. A method of treating a hyperproliferative disorder, comprising administering to a mammal a therapeutic combination in the form of a combination composition or alternating, the therapeutic combination comprising a therapeutically effective amount of a compound of formula I or II and a therapeutically effective amount of a chemotherapeutic agent selected from erlotinib, docetaxel, 5 -FU, gemcitabine, PD-0325901, cisplatin, carboplatin, paclitaxel, bevacizumab, trastuzumab, pertuzumab, temozolomide, tamoxifen, d ksorubitsina, Akti-1/2, HPPD, rapamycin, and lapatinib; ! where the compound of formula I and II has the structure:! ! or stereoisomers, geometric isomers, tautomers or their pharmaceutically acceptable salts, where! R1 is selected from H, F, Cl, Br, I, CN, - (CR14R15) mNR10R11, -C (R14R15) nNR12C (= Y) R10, - (CR14R15) nNR12S (O) 2R10, - (CR14R15) mOR10, - (CR14R15) nS (O) 2R10, - (CR14R15) nS (O) 2NR10R11, -C (OR10) R11R14, -C (= Y) R10, -C (= Y) OR10, -C (= Y) NR10R11, -C (= Y) NR12OR10, -C (= O) NR12S (O) 2R10, -C (= O) NR12CR14R15) mNR10R11, -NO2, -NR12C (= Y) R11, -NR12C (= Y) OR11, - NR12C (= Y) NR10R11, -NR12S (O) 2R10, -NR12SO2NR10R11, -SR10, -S (O) 2R10, -S (O) 2NR10R11, -SC (= Y) R10, -SC (= Y) OR10, C1-C12 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C12 carbocyclyl, C2-C20 heterocyclyl, C6-C20 aryl and C1-C20 heteroaryl; ! R2 is selected from H, F, Cl, Br, I, CN, CF3, -NO2, -C (= Y) R10, -C (= Y) OR10, -C (= Y) NR10R11, - (CR14R15) mNR10R11, - (CR14R15) nOR10, - (CR14R15) t-NR12C (= O) (CR14R15) NR10R11, -NR12C (= Y) R10, -NR12C (= Y) OR10, -NR12C (= Y) NR10R11, -NR12SO2R10, OR10 , -OC (= Y) R10, -OC (= Y) OR10, -OC (= Y) NR10R11, -OS (O) 2 (OR10), -OP (= Y) (OR10) (OR11), -OP (OR10) (OR11), SR10, -S (O) R10, -S (O) 2R10, -S (O) 2NR10R11, -S (O) (OR10), -S (O) 2 (OR10), - SC (= Y) R10, -SC (= Y) OR10, -SC (= Y) NR10R11, C1-C12 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C12 carbocyclyl, C2-C20 heterocyclyl, C6-C20 aryl and C1-C20 heteroaryl ; ! R3 is a carbon-linked monocyclic heteroaryl, carbon-linked fused bicyclic C3-C20 heterocyclyl or carbon-linked fused bicyclic |
| priorityDate | 2007-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 198.